Are You Eating Pork Injected With Merck’s mRNA Livestock Vaccine?
/Story at a glance:
For the last couple of years, I’ve recommended not eating pork due to its high linoleic acid (LA) content, but there’s an even bigger reason to avoid it now. Since 2018, pork producers have been using customizable mRNA-based “vaccines” on their herds.
The very first RNA-based livestock vaccine, a swine influenza (H3N2) RNA shot licensed in 2012, was developed by Harrisvaccines. The company followed up with an avian influenza mRNA shot in 2015. Harrisvaccines was acquired by Merck Animal Health later that year.
CureVac developed an mRNA-based rabies shot for pigs in 2016.
The swine vaccine platform Sequivity, introduced in 2018, was developed by Merck in partnership with Moderna. Sequivity can produce endlessly customized “vaccines,” none of which undergo safety testing.
Americans have been eating pork treated with gene therapy for nearly five years already, and even more of our meat supply is about to get the same treatment. mRNA-lipid nanoparticle shots for avian influenza are in the works, as are mRNA shots for cows. Lobbyists for the Cattlemen’s Association recently confirmed they intend to use mRNA “vaccines” in cattle, which might affect both dairy and beef.
Missouri House Bill 1169 would require labeling of products that can alter your genes. It would also require companies to share information about the potential transmissibility of gene-altering interventions, and asserts that fully informed consent must be given for all vaccines, gene therapies and medical interventions.
From [HERE] For the last couple of years, I’ve recommended not eating pork due to its high linoleic acid (LA) content, but there’s an even bigger reason to avoid it now.
Since 2018, pork producers have been using customizable mRNA-based “vaccines” on their herds, and this has slipped completely under the radar. I myself just found out about it.
As described on Merck’s animal health website:
“A revolutionary swine vaccine platform, SEQUIVITY harnesses RNA particle technology to create customized prescription vaccines against strains of influenza A virus in swine, porcine circovirus (PCV), rotavirus and beyond. It’s supported by a sophisticated dashboard filled with comprehensive data and insights …
“Sequivity is a custom swine vaccine platform … Sequivity only targets swine pathogen gene sequences of interest. Doesn’t replicate or cause disease, delivering pathogen information to the immune system … There’s no need to transfer or handle live material like autogenous, killed or modified live vaccines …
“Targets existing and evolving swine pathogens, including diseases not covered by conventional swine vaccines. Allows for the creation of multivalent formulations by blending RNA particles to target multiple swine pathogens in one shot.”
First RNA ‘vaccine’ for livestock licensed in 2012
Merck was not alone in developing veterinary mRNA shots, however. They weren’t even first on the scene, although they later acquired the company that started it all.
The very first RNA-based livestock vaccine, a swine influenza (H3N2) RNA shot, was licensed over a decade ago in 2012, and was developed by Harrisvaccines. The company followed up with an avian influenza mRNA shot in 2015. Harrisvaccines was acquired by Merck Animal Health later that year.
CureVac developed an mRNA-based rabies shot for pigs in 2016. (On a side note, they began conducting human rabies shot trials in 2020 in response to the World Health Organization’s goal to achieve “zero human rabies deaths by 2030.”)
In 2016, Bayer also partnered with BioNTech to develop mRNA “vaccines” for both livestock and pets, but it doesn’t appear they ever launched anything.
So, in retrospect, it appears Americans have been eating pork treated with gene therapy for the past five years, and even more of our meat supply is about to get contaminated with the same treatment.
In addition to the avian influenza RNA shot for chickens licensed in 2015, newer mRNA-lipid nanoparticle shots for avian influenza are also in the works.
Iowa State University is also working on an mRNA shot for cows, and lobbyists for the Cattlemen’s Association recently confirmed they intend to use mRNA “vaccines” in cattle, which might affect both dairy and beef.
Merck and Moderna: Partners in mRNA jab race since 2015
The same year Merck purchased Harrisvaccines (2015), it also entered into a partnership with Moderna to develop a number of undisclosed mRNA “vaccines.” It was slated to be a three-year collaboration, with a one-year optional extension, in which Merck would perform research and development and commercialization of five potential products using Moderna’s mRNA technology.
As reported by Genetic Engineering & Biotechnology News at the time:
“Moderna has agreed to design and synthesize the mRNA product candidates directed against selected targets through its mRNA Therapeutics™ platform.
“The platform builds on the discovery that modified mRNA can direct the body’s cellular machinery to produce nearly any protein of interest — ranging from native proteins to antibodies and other entirely novel protein constructs with therapeutic activity inside and outside of cells.”
Endless customization, zero safety testing
Sequivity, introduced in 2018, was one of the products that came out of that partnership. As explained by Merck (both on its website and in the video below), Sequivity is not so much a single vaccine as it is a platform that can be endlessly customized — all without additional safety analyses over and beyond the initial ridiculously inadequate testing.
As noted by Zoetis, the largest producer of veterinary drugs and vaccines:
“Sequivity has safety and efficacy studies based on the platform with a historical initial isolate, not likely the isolate that customers would be requesting in their product.”
Sequivity is customized as follows:
Pathogen is collected and sent to a diagnostic lab.
The gene of interest is sequenced and sent electronically to Sequivity analysts.
A synthetic version of the gene of interest is synthesized and inserted into the RNA production platform.
The RNA particles released from incubated production cells are harvested and formulated into a customized “vaccine.”
Using this platform, a customized “vaccine” can be created in as little as eight weeks. Now, what could go wrong by not testing every new shot for safety? [MORE]
